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Non-steroidal anti-inflammatory drugs after hip
replacement
Inhibit ectopic bone growth but do not reduce pain or disability
The risks of cardiovascular and cerebrovasculartoxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs)1 2 have
prompted reappraisal of the use of these drugs and led
to the inclusion of “black box” warnings in related pre-
scribing information in the United States.3 The
European Medicines Agency may also extend its warn-
ings, given that the Medicines and Healthcare Products
Regulatory Agency is considering unpublished data
from a new clinical trial4 along with all other evidence
and is seeking expert advice this month from the
Commission on Human Medicines (MHRA, personal
communication, 2006).
Clinicians now avoid the use of NSAIDs in patients
with established atheromatous disease. In this week’s
BMJ, however, Fransen and colleagues remind us that
this class of drugs has many potential uses including
inhibition of ectopic bone formation after joint
replacement and postoperative pain relief.5 The
authors report a randomised placebo controlled trial
of a modest two week dose of postoperative ibuprofen
(1200 mg a day) on pain and disability from ectopic
bone formation a median of eight months after hip
replacement. The trial found no effect of NSAIDs on
pain and disability.
This work is interesting for three reasons. Firstly,
this is a large and largely well conducted study
concerning the most common and effective interven-
tion for end stage hip disease—joint replacement. Sec-
ondly, it is important to publish such a relevant
negative study, because publication biases undermine
scientific progress and limit the usefulness of
systematic reviews.6 Finally, even though the primary
outcome was negative, the study was useful because it
showed that ibuprofen reduced the risk of forming
ectopic bone by 31% (95% confidence interval 56% to
83%), and that the effect increased with increasing
degrees of ectopic ossification. Most would regard this
as clinically relevant only if clinical outcomes (pain and
function) were influenced, which they were not. So, was
the difference in bone formation real and, if it was, why
did the effect of treatment on ectopic ossification not
reduce pain and disability?
The effect of NSAIDs on bone formation was
probably real. This effect has already been established
by a Cochrane review,7 and Fransen and colleagues’
study in 20 centres with 900 patients is large enough to
have generalisability across Australasia and perhaps
more widely. Nevertheless, these results showing no
clinical benefit from lowering the risk of ectopic bone
formation serve to remind us that guidelines in routine
care should be based on clinically important outcomes,
not unproved surrogate outcomes.8
Previous evidence suggests that cyclo-oxygenase-2
(COX 2) inhibitors might be more effective in inhibit-
ing ectopic bone formation,9 provide good postopera-
tive pain relief, and cause less bleeding than
non-selective inhibitors. They might be an attractive
alternative to NSAIDs, but this remains to be
confirmed in a randomised controlled trial. And,
importantly, treatment with selective or non-selective
COX 2 inhibitors after joint replacement may
compromise integration of the implant into the host
bone bed, increasing the risk of late loosening of the
implant and the need for repeated surgery.10 While this
potentially important adverse effect is being explored
in laboratory, clinical, and registry studies, it seems
prudent to exercise caution in using COX 2 inhibitors
after joint replacement.
The study by Fransen and colleagues has some
limitations. The heterogeneous inclusion criteria
impede direct comparison with other trials, and the
lack of analysis of clinical subgroups bars exploration
of the types of patients who might respond best to
treatment. This study cannot answer questions about
whether a longer course, a different NSAID, or more
prolonged follow-up might yield clinical differences
between treatment and placebo groups. Moreover, the
authors did not discuss whether the outcome measures
were sufficiently discriminating to detect differences,11
especially when missing data were imputed by carrying
the baseline observation forward and when there may
have been a measurement artefact such as a floor effect
in the main outcome measures.
There will never be a perfect clinical trial, however.
The challenge for doctors lies in interpreting the
relevance of such evidence to clinical practice. In this
study by Fransen and colleagues the increase in major
bleeding events in the patients who took NSAIDs,
while numerically small, is statistically significant and
reminds us that bleeds remain an important cause of
morbidity and mortality with this class of drugs.12 The
frequency of bleeding events would almost certainly be
increased by the use of higher doses and more
prolonged administration of NSAIDs; hence further
studies to test these interventions could be too risky.
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On balance, this study shows that NSAIDs should not
be given routinely after hip replacement surgery, but
they might be used cautiously after due consideration
of the overall likely benefits and risks to the patient.
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Ageism in services for transient ischaemic attack
and stroke
Could be cut by emulating successful efforts against ageism in heart disease care
Societies based on market driven economies havedeeply embedded value systems that inherentlyfavour economically productive younger citizens
and marginalise non-productive older citizens. Health
services reflect the societies they serve. One manifesta-
tion of institutionalised ageism is overt and covert
rationing of health care that discriminates against
older people. This might be acceptable if the clinical
outcomes of treating older people were inferior. How-
ever, the notion of age based rationing of treatment has
become unsustainable and unethical as robust
evidence has accumulated that shows comparable out-
comes for treatment of older and younger people.
In England, decades of health service underfund-
ing have provided an environment in which ageism has
flourished—it is endemic.1 Whenever a clinical stone is
turned over, ageism is revealed—for example, in cancer
services,2 coronary care units,3 prevention of vascular
disease,4 and in mental health services.5 To this list we
must now add the management of transient ischaemic
attacks and minor strokes, as a study in this week’s BMJ
by Fairhead and Rothwell shows.6
Fairhead and Rothwell investigated the manage-
ment of transient ischaemic attacks and minor stroke
in routine clinical services compared with a nested
population receiving care based on national clinical
practice guidelines.6 In the routine service they found
substantial under-referral for carotid artery imaging
and subsequent undertreatment of symptomatic
carotid artery stenosis in patients over the age of 80.
The two study populations were comparable in terms
of age, sex, and socioeconomic status and, for patients
under 80, similar rates of performing clinical investiga-
tions were seen. Avoiding a disabling stroke is a prior-
ity in all patients, irrespective of age, and the authors
conclude that the older patients in the population
given routine care were discriminated against.
This study lacked, however, a view from the practi-
tioners who invisibly contributed by providing care for
these patients. Did they really make inconsistent
clinical choices biased by the patients’ ages? One quali-
tative study of the management of cardiovascular
disease that identified ageism as a factor in suboptimal
care for older people showed that doctors felt
uncertain about the best and safest clinical practice,
were unaware of the latest relevant research evidence,
and were hampered by problems with local services.7
From an older person’s perspective this apparently
benign form of age discrimination is just as damaging
as blatant ageism because older patients are still denied
potentially beneficial treatments openly available to
younger people. But understanding the reasons for
such discrimination does suggest a role for education
as an important corrective.
At the heart of the educational argument for stroke
lies the counterintuitive notion that carotid endarterec-
tomy for symptomatic carotid artery stenosis confers
Editorials
Research p 525
BMJ 2006;333:507–8
508 BMJ VOLUME 333 9 SEPTEMBER 2006 bmj.com
